Clinical Data

Proof of Concept

Status: Completed 2014

Number of Patients: 28

Primary Endpoint: IOP reduction at 6 months

The proof of concept of our technology was successfully achieved by a randomized controlled trial (RCT) performed in Israel, published in the Journal of Glaucoma.

Two groups of 14 patients each were treated: the control group was treated with the traditional SLT, delivering 100 laser beams manually to the treatment area through a gonioscopy lens.

The study group was treated with the traditional SLT device, but implementing BELKIN’s external method, delivering 100 laser beams to the trabecular meshwork through the sclera without lens. We achieved the same effectiveness with less side effects.

The results clearly showed that after one year of follow-up there was no difference in IOP reduction between the conventional approach and BELKIN’s innovative approach. With respect to side-effects and patient discomfort, the external BELKIN application was superior to the conventional method.

According to the ophthalmic literature, SLT treatment achieves a reduction in IOP of about 20% for 1 to 5 years in 80% of patients. In the POC clinical trial, a reduction of 23.7% was achieved after 3 months of follow up in 80% of patients.

View Full Publication

GLAUrious – Multicenter Randomized Controlled Study

Status: In Process

Number of Patients: 124

Primary Endpoint: IOP reduction at 6 months

This study is our pivotal multicenter randomized controlled study to assess the non-inferiority of the DSLT compared to SLT. The study is supported by a grant from the European commission (Horizon 2020 program).

There are two participating sites in the UK, one in Italy and 5 in Israel.

View clinicaltrials.gov
View GLAUrious website

About Cookies On This Site

We use cookies to offer you a better experience and analyze site traffic. This website is based in the United States and by continuing to use this website or by using our services, you consent to the use of cookies in accordance with our privacy policy.